AMENDMENT TRANSMITTAL LETTER					Docket No. BSX 234 US1	
Application No.		Filing Date		Examiner	Art Unit	
09/473,830-Conf. #1518		December 28, 1999		S. L. Chen	1632	
pplicant(s): Jef	frey M. Leiden	et al.	•			
vontion:	IENT AND STA MBINANT ADE			SFER TO CARDION VECTORS	NYOCYTES USING	
		THE COMMI				
	ewith is an ame			• •		
he fee has bee	n calculated an	d is transmitte	d as shown b	elow.		
CLAIMS AS AMENDED						
	Claims Remaining After Amendment	Highest Number Previously Paid	Number Extra Claims Present	Rate		
Total Claims	17	- 27 =		Х		
Independent Claims	1	- 1 =		х		
Multiple Dependent Claim (check if applicable)						
Other fee (pleas	se specify):					
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT:						
x Large Entity Small Entity						
No addition	al fee is require	d for this amer	ndment.	_		

TOTAL ADDITIONAL FEE FOR THIS AMENDA		
x Large Entity	Small Entity	/
No additional fee is required for this amendment	ent.	
Please charge Deposit Account No. A duplicate copy of this sheet is enclosed.	in the amount of \$	•
A check in the amount of \$	to cover the filing fee is end	closed.
Payment by credit card. Form PTO-2038 is a	ittached.	
The Director is hereby authorized to charge aas described below. A duplicate copy of this	·	lo06-2375
x Credit any overpayment.		
x Charge any additional filing or application pro	ocessing fees required under	37 CFR 1.16 and 1.17
maryine Schofield	Dated:	June 16, 2005

Mary Anne Schofield
Attorney Reg. No.: 36,669

FULBRIGHT & JAWORSKI L.L.P. 801 Pennsylvania Avenue, N.W. Washington, DC 20004-2623 (202) 662-4584

Docket No.: BSX 234 US1/10408799

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re Patent Application of: Jeffrey M. Leiden et al.

Application No.: 09/473,830

Confirmation No.: 1518

Filed: December 28, 1999

Art Unit: 1632

For: EFFICIENT AND STABLE IN VIVO GENE

Examiner: Shin Lin Chen

TRANSFER TO CARIOMYOCYTES

AMENDMENT

Dear Sir:

This is in response to a non-final Office Action dated March 16, 2005 in this application.

Please amend the application as follows.

Amendments to the claims begin on page 2.

Remarks section begins on page 4.